The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
| العنوان: | The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( |
|---|---|
| المؤلفون: | Shweta Urva, Emily C Beebe, Michael A. Nauck, Charles Benson, Xuewei Cui, Tamer Coskun, Corina Loghin, Libbey S. O’Farrell, Daniel A. Briere, Axel Haupt |
| المصدر: | Diabetes, Obesity and Metabolism. 22:1886-1891 |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Agonist, endocrine system, medicine.medical_specialty, Gastric emptying, medicine.drug_class, business.industry, Endocrinology, Diabetes and Metabolism, Semaglutide, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Glucagon-like peptide-1, Acetaminophen, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Internal Medicine, medicine, Dulaglutide, business, Receptor, Glucagon-like peptide 1 receptor, medicine.drug |
| الوصف: | The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies. GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo. GE was assessed by acetaminophen absorption. In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide; however, these acute inhibitory effects were abolished after 2 weeks of treatment. GIP analogue alone had no effect on GE or on GLP-1's effect on GE. In participants with and without T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a single dose. This effect diminished after multiple doses of tirzepatide or dulaglutide in healthy participants. In participants with T2DM treated with an escalation schedule of tirzepatide 5/5/10/10 or 5/5/10/15 mg, a residual GE delay was still observed after multiple doses. These data suggest that tirzepatide's activity on GE is comparable to that of selective GLP-1RAs. |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::98a07224445c496000bf7c6feab8566eTest https://doi.org/10.1111/dom.14110Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........98a07224445c496000bf7c6feab8566e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|